Home > Projects > Cancer > HIFU-CHEM    
Cardiovascular diseases
Neurodegenerative diseases
Infection and immunity
Translational Research IT (TraIT)
De eerste resultaten van HIFU-CHEM (in Dutch)
MR-HIFU (Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound) is een nieuwe behandelmethode voor pijnlijke botuitzaaiingen. Het gaat om een behandeling, met het doel de pijn te verminderen en kwaliteit van leven te behouden of waar mogelijk te verbeteren.
 - Tesla 7 (Kopie).jpgDe behandeling wordt alleen toegepast bij patiŽnten in de palliatieve fase, dit wil zeggen dat zij met de reguliere behandelingen niet meer beter kunnen worden. MR-HIFU is goedgekeurd als veilige behandeling voor patiŽnten met pijnlijke botuitzaaiingen.
De patiŽnt kan dezelfde dag al naar huis.
Het UMC Utrecht is het eerste en voorlopig enige ziekenhuis waar momenteel de pijnbehandeling met ultrageluid plaatsvindt. De MR-HIFU werkzaamheden vallen binnen het HIFU-CHEM project van CTMM. Het totale projectbudget is 6.7 M Euro, het project loopt van 1 januari 2011 tot 31 december 2014.
Meer informatie over de pijnbehandeling (Nederlands).
Meer informatie over het CTMM HIFU-CHEM project vindt u hieronder (Engelstalig).
Project information
Application of MRI-guided HIFU to Improve Cancer Chemotherapy with Temperature-Sensitive Targeted Nanomedicines
The HIFU-CHEM project: chemotherapy in focus

Extensive research in the field of tumour-targeted drug delivery during the last decades has resulted in a great variety of drug carrier systems designed to preferentially localize in tumour tissue. An example of tumour-targeted nanomedicine is a liposome containing an anticancer drug. Once the liposomal nanomedicine has localized in the tumour tissue, the drug must be released at a sufficient rate and extent to become therapeutically active. It is this issue, which represents a major challenge, as liposomes are generally designed such that they show a high degree of stability in the bloodstream to avoid premature release of the drug before arrival at the target site, thus keeping side effects minimal and the targeting effect maximal.
In this project, ultrasound is applied to mildly raise the temperature within tumour sites to trigger Ďon demand' the release of drug from temperature-sensitive liposomes once they have entered the tumour area. The newly developed liposomal formulation containing doxorubicin as the antitumour drug (ThermoDoxģ) will be used for this purpose. Ultrasound is sound with a frequency so high that it cannot be heard by humans. It is possible to focus ultrasound in such a way that all acoustic energy ends up in one location (so-called high intensity focused ultrasound (HIFU)). In this focal point, local heating of the tissue will occur, which can be used to kill tumour cells. In order to make sure that the HIFU only hits the tumour area, the HIFU treatment procedure will be carried out inside an MRI scanner, which allows continuous imaging of the tumour and the surrounding healthy tissue. MRI can be used to acquire temperature maps of tissue to control the HIFU heating procedure and to study the release of drugs from temperature-sensitive liposomes. The combination of MRI and focused ultrasound is called ďMagnetic Resonance Imaging-guided HIFU (MRgHIFU)Ē.
In the HIFU-CHEM project dedicated MRgHIFU technology will be applied to illustrate the potential of HIFU-mediated drug release from temperature-sensitive nanomedicine to increase the tumour concentration of chemotherapeutic drugs in patients with liver tumours and bone metastases from prostate cancer.

Principal Investigator:
 - Dhr Storm.jpg
Gert Storm, Utrecht University

Gert Storm: "The HIFU-CHEM project is unique in the nanomedicine field, as it is the first project aimed at tailored chemotherapy in cancer patients by combining targeted liposomal drug delivery with imaging-guided focused ultrasound."
The research interests of Professor Gert Storm are in the fields of biopharmaceutics and drug targeting. In 1988-1989 he was a visiting scientist at Liposome Technology Inc. in Menlo Park, USA, and visiting assistant professor at the School of Pharmacy, UCSF, San Francisco. In 1990-1991 he was senior research scientist at Pharma Bio-Research Consultancy B.V. in Zuidlaren, The Netherlands. In September 1991 he took up his present position. In 1999, he was appointed adjunct professor at the Royal School of Pharmacy, Copenhagen. In 2000, he was appointed as professor (Drug Targeting chair) at Utrecht University. He is author/co-author of more than 300 original articles, reviews and book chapters, in the field of advanced drug delivery/drug targeting. He is co-ordinator of an Integrated Project (FP6) on targeted nanomedicines (MediTrans) based on the collaboration of 30 european partners and funded by the EC and industry.
contact: g.storm @
Partners in HIFU-CHEM
Industrial partners:
Academic partners:
Celsion Corp
UMC Utrecht
Philips Electronics Netherlands
Utrecht University
TU Eindhoven
National Institute of Health
HIFU-CHEM project presentation at the CTMM Annual Meeting 2010: PDF (download)
The three Public Private Partnerships BMM, CTMM and TI Pharma initiated a call for proposals for research focused on the interface of the three institutes: Imaging Guided and Targeted Drug Delivery.
The projects emerging from this joint call for proposals represent the first example of an interdisciplinary public-private consortium that encompasses competencies from all three institutes. Projects are performed by academia and industry in close cooperation.
HIFU-CHEM is one of the joint call projects funded by CTMM.
26 November 2010




© CTMM, Center for Translational Molecular Medicine | Contact | Login | Disclaimer